Vitiligo

Long underserved by a narrow armamentarium, patients with pigmentary disorders could soon see a new wave of oral and topical solutions to treat even the most challenging cases.

Ruxolitinib cream (Opzelura; Incyte) receives priority review of its supplemental New Drug Application as a treatment for patients with vitiligo.

Looking toward the future management of vitiligo, expert dermatologists close out their discussion on JAK inhibition and other novel therapy.

Shared insight from dermatologists on novel topical JAK inhibitor therapy being investigated as an option for patients with vitiligo.

A recent study examined the impact of virtual group visits to obtain community and education for pediatric vitiligo and alopecia areata patients and caregivers.

A brief review of the treatment armamentarium for vitiligo, as well as the prevalent unmet needs in that setting.

A recent JAAD study evaluated the correlation between F-VASI and T-VASI using patient- and physician-reported measures of clinical improvement, PaGIC-V and PhGVA.

Seemal Desai, MD, FAAD, and William Damsky, MD, PhD, discuss methods for managing a patient’s motivation and expectations when on therapy for vitiligo.

In this video interview, James Q Del Rosso, DO, tackles the clinical impact of JAK Inhibitors and how to deal with patient concern.

Expert perspectives on the diagnosis of vitiligo and considerations for improving provider awareness in dermatologist and community settings.

A comprehensive breakdown of the different classifications of vitiligo and how these may present clinically.

In this exclusive video interview, James Q Del Rosso, DO, gets into the details of JAK inhibitors, explaining how they work and cutting through the headlines around the treatments.

Shared insight on the psychological and social impact of vitiligo, along with practical advice on how to communicate with and support patients.

Expert dermatologists Seemal Desai, MD, FAAD, and William Damsky, MD, PhD, provide an overview of vitiligo, as an autoimmune disorder, and its prevalence.

The potential of JAK inhibitors and other emerging medications could answer demand for more treatment options for these challenging skin conditions. Read down below.

Ruxolitinib meets primary and secondary endpoints in phase 3 TRuE-V clinical trial program.

Investigators reported that patients in the vitiligo group reported worse general health, and were willing to pay more than 40% of their income for a cure.

A recent study evaluated the efficacy of the patient reported outcome measure instrument Clinical Evolution-Vitiligo for scoring nonsegmental vitiligo.

A study in the Journal of the American Academy of Dermatology investigated the maintenance of results of ruxolitinib cream in patients with vitiligo.

Incyte announced that ruxolitinib cream has received validation for its European marketing authorization application from the European Medicines Agency.

Combined therapies such as ultraviolet light and tab methotrexate were deemed effective in the management of vitiligo.

Neal Bhatia, MD, explores steroid alternatives in his presentation at the Fall Clinical Dermatology Conference.

Investigators believe the new instrument could be generalized to other chronic inflammatory skin diseases in future studies.

A study published in the Journal of the American Academy of Dermatology did a subgroup analysis of ruxolitinib cream for vitiligo patients.

In a recent review, authors examine the different mechanisms of melanocyte death in vitiligo, including genetic predisposition, oxidative stress, and innate vs adaptive immune activation.

Investigators reported a significant difference in the expansion rate of the skin lesion area in patients with vitiligo in just 3 months of treatment.

Investigators write that methods such as dermatoscopy can result in early recognition of unstable patches and lead to appropriate medical treatment for patients with vitiligo.

A new study showed about half of all vitiligo patients from a care system were burdened with the sleeping disorder.

In this first part of our coverage of “The Skin of Color Update Pre-Conference Virtual Symposium” held August 3, we review challenging cases of melasma, vitiligo, and post-inflammatory hyperpigmentation in skin of color patients.

Arcutis Biotherapeutics announced early termination of its phase 2a trial evaluating ARQ-252 as a potential treatment for vitiligo citing to inadequate local drug delivery to the skin.